In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Patients' journey of care following incident heart failure: diagnostic tests, treatments and care pathways in 93,000 patients

Session Young Investigator Award Session Population Sciences

Speaker Nathalie Conrad

Congress : ESC Congress 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Treatment, Other
  • Session type : Young Investigator Award Abstracts
  • FP Number : 1147

Authors : N Conrad (Oxford,GB), A Judge (Oxford,GB), J O Donnell (Oxford,GB), J Tran (Oxford,GB), M Nazarzadeh (Oxford,GB), D Canoy (Oxford,GB), J J V Mcmurray (Glasgow,GB), K Rahimi (Oxford,GB)

Authors:
N. Conrad1 , A. Judge1 , J. O'Donnell1 , J. Tran1 , M. Nazarzadeh1 , D. Canoy1 , J.J.V. McMurray2 , K. Rahimi1 , 1University of Oxford - Oxford - United Kingdom , 2University of Glasgow - Glasgow - United Kingdom ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 229

Background: In the UK, outpatient care of heart failure patients, including referrals to specialists, diagnostic investigations, and drug prescriptions, falls under the responsibility of general practitioners. A comprehensive assessment of physicians' adherence to essential care delivery components may help refine service delivery policies and prioritise further research, but current evidence base is limited.

Methods: We used linked primary and secondary electronic health records from the Clinical Practice Research Datalink (CPRD) of 93,000 individuals diagnosed with incident heart failure between 2002 and 2014. We investigated primary care follow-up rates, defined as a heart failure related primary care consultation within 12 months of incident diagnosis. Among those with primary care follow-up (n=47,946), we further explored guideline-indicated diagnostic tests within ± 6 months of diagnosis; and in eligible patients (those with reduced ejection fraction with no contraindication or intolerance) we investigated prescriptions for guideline-indicated drug treatments. Logistic regression models were used to examine odds ratios (OR) and 95% confidence intervals, adjusting for year of diagnosis, age, sex, region and socio-economic status.

Results: The proportion of patients with primary care follow-up, declined over time, from 63% in 2002 to 44% in 2014 (p<0.01). In parallel, among those with primary care follow-up, guideline-indicated diagnostic investigations and treatment initiation increased substantially. In 2014 77% of patients were referred for either a natriuretic peptides test, an echocardiogram or an electrocardiogram, compared with 33% in 2002 (p<0.01); while 63% of eligible patients were prescribed both beta-blockers (BB) and either an angiotensin-converting-enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) within 3 months of diagnosis, compared with 18% in 2002 (p<0.01). However, in 2014, the average daily dose prescribed in the 12 months following diagnosis remained far below guideline-indicated target dosages: 49% for ACE-I or ARB, 29% for BB; and showed no signs of consistent increment, despite guideline recommendations to regularly uptitrate doses. Men were more likely to receive guideline-indicated diagnostic tests (OR: 1.46 [1.41, 1.52]), treatments (OR: 1.28 [1.12, 1.47]), and primary care follow-up (OR: 1.22 [1.19, 1.25]). Patients aged over 75 years were less likely to receive treatments (OR: 0.71 [0.60,0.85]), and primary care follow-up (OR: 0.65 [0.59, 0.72]).

Conclusion: In the UK, general practitioners' uptake of guideline-indicated diagnostic tests and treatments have increased over time. However, medication dosages remain far below the guideline-indicated target dosages and significant care gaps were observed in women and the elderly. Moreover, the declining number of patients who receive heart failure care in the primary care setting is concerning and may affect the overall care of patients with heart failure.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are